Charles Calderaro III, Chief Technical Officer, joined Avidity Biosciences in January 2025. He has more than 35 years of experience in biotechnology, pharmaceutical, and cell and gene therapy company operations and in CMC drug development. Prior to joining Avidity, Mr. Calderaro served as Chief Technical Officer for Shoreline Biosciences, where he was responsible for advancing programs in oncology and autoimmune diseases and developing scalable bioprocesses for manufacturing gene editing and cell therapies. Prior to Shoreline, he served as Global Head of Technical Operations at Kite Pharma, a Gilead Company, and Senior Vice President, Global Manufacturing at BioMarin. In addition, he previously held roles of increasing responsibility during his 14-year tenure at Genentech, a member of the Roche Group, and at Aventis Behring LLC (now CSL Behring). Mr. Calderaro was also previously a commissioned officer in the U.S. Navy. He earned his M.B.A. from Texas Christian University, his M.S. in Nuclear Engineering from the U.S. Naval Nuclear Power School, and his B.S. in Electrical Engineering from the University of Notre Dame.